Oxford BioMedica Plc has signed a contract with Novartis to supply the Swiss company with lentiviral vector material for clinical trials involving a new immunotherapy. The contract is valued at up to £4 million. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
